Title : AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.

Pub. Date : 2005 Jul 1

PMID : 16000593






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 AMN107 is a novel, orally bioavailable ATP-competitive inhibitor of Bcr-Abl. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
3 AMN107 inhibited autophosphorylation of Bcr-Abl kinase more effectively than imatinib in all cell lines. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens